ReviewCell adhesion & migration
The mesenchymal tumor microenvironment: a drug-resistant niche.
Review in Cell adhesion & migration. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer.Oncotarget · 2015Trial
- Immune cross talk and therapeutic advances in lactate metabolism in the tumor microenvironment (Review).Experimental and therapeutic medicine · 2026Review
- Identification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.Stem cells international · 2024Article
- Mesenchymal Stem Cell-Secreted Exosome Promotes Chemoresistance in Breast Cancer via Enhancing miR-21-5p-MediatedMolecular therapy oncolytics · 2020Article
- Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation.Haematologica · 2020Article
- Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment.Breast cancer (Dove Medical Press) · 2019Article
- Article
- Current diagnostics and treatment of fibrosarcoma -perspectives for future therapeutic targets and strategies.Oncotarget · 2017Review
- The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Molecular cancer therapeutics · 2017Article
- Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets.Nature reviews. Drug discovery · 2017Review
- The crucial role of emilin 1 gene expression during progression of tumor growth.Journal of cancer research and clinical oncology · 2016Article
- NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Journal of nanobiotechnology · 2016Review
- Oncostatic-Cytoprotective Effect of Melatonin and Other Bioactive Molecules: A Common Target in Mitochondrial Respiration.International journal of molecular sciences · 2016Review
- Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer.Cell cycle (Georgetown, Tex.) · 2015Article
- AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827.Oncology reports · 2015Article
- Microenvironmental regulation of therapeutic response in cancer.Trends in cell biology · 2015Review
- Cancer stem cell theory and the warburg effect, two sides of the same coin?International journal of molecular sciences · 2014Article
- Miniaturized pre-clinical cancer models as research and diagnostic tools.Advanced drug delivery reviews · 2014Review
- Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy.Frontiers in oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug and radiation resistance represent a challenge for most anticancer therapies. Diverse experimental approaches have provided evidence that the tumor-associated microenvironment constitutes both a protective shell that impedes drug or radiation access and a permissive or promotive microenvironment that encourages a nurturing cancer (i.e., cancer stem cell) niche where tumor cells overcome treatment- and cancer-induced stresses. Better understanding of the effects of the tumor microenvironment on cancer cells before, during and immediately after chemo- or radiotherapy is imperative to design new therapies aimed at targeting this tumor-protective niche. This review summarizes some of the known mesenchymal stromal effects that account for drug resistance, the main signal transduction pathways associated with this resistance and the therapeutic efforts directed to increase the success of current therapies. Special emphasis is given to environment-mediated drug resistance in general and to cell adhesion-mediated drug resistance in particular.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.